{"cluster": 63, "subcluster": 4, "abstract_summ": "Data mining of prescription records of COVID\u201019 patients will not cancel the need for conducting controlled clinical trials, but could substantially assist in trial design, drug choice, inclusion and exclusion criteria, and prioritization.More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19.In the difficulty where new synthesized drug cannot be applied immediately to patients, \u201cconventional drug in new use\u201d becomes a feasible solution.The new zoonotic coronavirus (SARS-CoV-2) responsible for coronavirus disease (COVID-19) is a new strain of coronavirus not previously seen in humans and which appears to come from bat species.Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome.", "title_summ": "[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].[Pharmacotherapeutics for the new coronavirus pneumonia].[Pharmacotherapeutics for the New Coronavirus Pneumonia].Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert OpinionA new pharmacological approach based on remdesivir aerosolized administration on sars-cov-2 pulmonary inflammation: a possible and rational therapeutic applicationPharmacologicaltreatment of COVID-19: lights and shadowsRemdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidenceClinical trials on drug repositioning for COVID-19 treatmentRepurposing current therapeutics for treating COVID\u201019: A vital role of prescription records data miningLiterature-based review of the drugs used for the treatment of COVID-19", "title_abstract_phrases": "More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19.In the difficulty where new synthesized drug cannot be applied immediately to patients, \u201cconventional drug in new use\u201d becomes a feasible solution.Data mining of prescription records of COVID\u201019 patients will not cancel the need for conducting controlled clinical trials, but could substantially assist in trial design, drug choice, inclusion and exclusion criteria, and prioritization.Pharmacologicaltreatment of COVID-19: lights and shadowsAt the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus.A new pharmacological approach based on remdesivir aerosolized administration on sars-cov-2 pulmonary inflammation: a possible and rational therapeutic applicationThe new zoonotic coronavirus (SARS-CoV-2) responsible for coronavirus disease (COVID-19) is a new strain of coronavirus not previously seen in humans and which appears to come from bat species."}